Binding of the Epstein-Barr virus to human platelets causes the release of transforming growth factor-beta.
Human platelets bear on their surface complement receptor type II (CR2), which is also the receptor for the EBV. Although the cross-linking of these receptors causes activation and aggregation of platelets, no immunologic consequence of the potential binding of EBV to these receptors on human platelets has ever been described. We report here that binding of EBV to human platelets causes the release of TGF-beta from the latter. Both infectious and UV-inactivated noninfectious viral particles can mediate this release. Anti-CR2 mAb OKB7, which blocks the binding of EBV to CR2, also blocks the EBV-mediated release of TGF-beta. Furthermore, platelets recovered from the initial incubation no longer release TGF-beta upon subsequent incubation with EBV. Since TGF-beta is a potent immunosuppressive agent, its release from platelets upon binding of EBV may play a role in the pathogenesis of EBV-associated diseases.
Ahmad
A
A
Laboratory of Immunovirology, University of Montreal and Ste-Justine Hospital, Quebec, Canada. ahmada@justine.umontreal.ca
Menezes
J
J
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001792:Blood Platelets / Q000276:immunology / Q000378:metabolism* / Q000821:virology*; D004854:Herpesvirus 4, Human / Q000502:physiology*; D006801:Humans; D007700:Kinetics; D017464:Receptors, Complement 3d / Q000276:immunology; D011991:Receptors, Virus / Q000097:blood / Q000502:physiology*; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000097:blood*
D000911:Antibodies, Monoclonal; D017464:Receptors, Complement 3d; D011991:Receptors, Virus; D016212:Transforming Growth Factor beta